Variation in anticoagulant recommendations by the guidelines and decision tools among patients with atrial fibrillation

Healthcare (Switzerland)

Volumn 3, Issue 1, 2015, Pages 130-145

  Shewale, Anand ^a   Johnson, Jill ^b   Li, Chenghui ^a   Nelsen, David ^c   Martin, Bradley ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atrial fibrillation; Decision tools; Guidelines; Oral anticoagulants; Overuse; Recommendations; Underuse; Warfarin

Indexed keywords

EID: 84969910596     PISSN: None     EISSN: 22279032     Source Type: Journal    
DOI: 10.3390/healthcare3010130     Document Type: Article

References (29)

1. Singer, D.E.; Albers, G.W.; Dalen, J.E.; Fang, M.C.; Go, A.S.; Halperin, J.L.; Lip, G.Y.; Manning, W.J. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133, 546S–592S.
2. Garg, N.; Kumar, A.; Flaker, G.C. Antiplatelet therapy for stroke prevention in atrial fibrillation. Mo. Med. 2010, 107, 44–47.
3. Ogilvie, I.M.; Newton, N.; Welner, S.A.; Cowell, W.; Lip, G.Y. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am. J. Med. 2010, 123, 638–645.
4. Gage, B.F.; Boechler, M.; Doggette, A.L.; Fortune, G.; Flaker, G.C.; Rich, M.W.; Radford, M.J. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000, 31, 822–827.
5. Cohen, N.; Almoznino-Sarafian, D.; Alon, I.; Gorelik, O.; Koopfer, M.; Chachashvily, S.; Shteinshnaider, M.; Litvinjuk, V.; Modai, D. Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke 2000, 31, 1217–1222.
6. Chang, H.J.; Bell, J.R.; Deroo, D.B.; Kirk, J.W.; Wasson, J.H. Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. Arch. Inter. Med. 1990, 150, 83–86.
7. Beyth, R.J.; Antani, M.R.; Covinsky, K.E.; Miller, D.G.; Chren, M.M.; Quinn, L.M.; Landefeld, C.S. Why isn’t warfarin prescribed to patients with nonrheumatic atrial fibrillation? J. Gen. Inter. Med. 1996, 11, 721–728.
8. Akao, M.; Chun, Y.H.; Esato, M.; Abe, M.; Tsuji, H.; Wada, H.; Hasegawa, K.; Fushimi AF Registry Investigators. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ. J. 2014, 78, 2166–2172.
9. Lahaye, S.A.; Gibbens, S.L.; Ball, D.G.; Day, A.G.; Olesen, J.B.; Skanes, A.C. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur. Heart J. 2012, 33, 2163–2171.
10. January, C.T.; Wann, L.S.; Alpert, J.S.; Calkins, H.; Cleveland, J.C., Jr.; Cigarroa, J.E.; Conti, J.B.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2014, 64, e1–e76.
11. Casciano, J.P.; Singer, D.E.; Kwong, W.J.; Fox, E.S.; Martin, B.C. Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am. J. Cardiovasc. Drugs 2012, 12, 313–323.
12. You, J.J.; Singer, D.E.; Howard, P.A.; Lane, D.A.; Eckman, M.H.; Fang, M.C.; Hylek, E.M.; Schulman, S.; Go, A.S.; Hughes, M.; et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141, e531S–e575S.
13. Camm, A.J.; Lip, G.Y.; de Caterina, R.; Savelieva, I.; Atar, D.; Hohnloser, S.H.; Hindricks, G.; Kirchhof, P.; ESC Committee for Practice Guidelines (CPG); Bax, J.J.; et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012, 33, 2719–2747.
14. Wess, M.L.; Schauer, D.P.; Johnston, J.A.; Moomaw, C.J.; Brewer, D.E.; Cook, E.F.; Eckman, M.H. Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J. Gen. Inter. Med. 2008, 23, 411–417.
15. DAWN AC Anticoagulation Software—4S Dawn Clinical Software. RefGrab-It. Available online: http://www.4s-dawn.com/products/anticoagulation/dawnac/(accessed on 7 February 2014).
16. Medical Disclaimer—AFib.ca. RefGrab-It. Available online: http://www.afib.ca/Disclaimer. (accessed on 7 February 2014).
17. Gage, B.F.; Waterman, A.D.; Shannon, W.; Boechler, M.; Rich, M.W.; Radford, M.J. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001, 285, 2864–2870.
18. Lip, G.Y.; Nieuwlaat, R.; Pisters, R.; Lane, D.A.; Crijns, H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010, 137, 263–272.
19. Fang, M.C.; Go, A.S.; Chang, Y.; Borowsky, L.H.; Pomernacki, N.K.; Udaltsova, N.; Singer, D.E. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 2011, 58, 395–401.
20. Lip, G.Y.; Frison, L.; Halperin, J.L.; Lane, D.A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J. Am. Coll. Cardiol. 2011, 57, 173–180.
21. Singer, D.E.; Chang, Y.; Fang, M.C.; Borowsky, L.H.; Pomernacki, N.K.; Udaltsova, N.; Go, A.S. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Inter. Med. 2009, 151, 297–305.
22. Go, A.S.; Hylek, E.M.; Chang, Y.; Phillips, K.A.; Henault, L.E.; Capra, A.M.; Jensvold, N.G.; Selby, J.V.; Singer, D.E. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003, 290, 2685–2692.
23. Go, A.S.; Hylek, E.M.; Borowsky, L.H.; Phillips, K.A.; Selby, J.V.; Singer, D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Inter. Med. 1999, 131, 927–934.
24. Kate, F.; Jonah, B.; Bruce, P.; Kosuke, I.; Winghan Jacqueline, K. Utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation. 2012, 5, 157–168.
25. Hylek, E.M.; Go, A.S.; Chang, Y.; Jensvold, N.G.; Henault, L.E.; Selby, J.V.; Singer, D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl. J. Med. 2003, 349, 1019–1026.
26. Lip, G.; Bassand, J.; Fitzmaurice, D.; Goldhaber, S.; Goto, S.; Verheugt, F.; Turpie, A.; Mueller, I.; Rushton-Smith, S.; Kakkar, A. Inappropriate utilization of anticoagulation in patients with atrial fibrillation: The global anticoagulant registry in the field (GARFIELD) registry. J. Am. Coll. Cardiol. 2012, 59, E670.
27. Steinberg, B.A.; Kim, S.; Thomas, L.; Fonarow, G.C.; Hylek, E.; Ansell, J.; Go, A.S.; Chang, P.; Kowey, P.; Gersh, B.J.; et al. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 2014, 129, 2005–2012.
28. Singer, D.E.; Chang, Y.; Borowsky, L.H.; Fang, M.C.; Pomernacki, N.K.; Udaltsova, N.; Reynolds, K.; Go, A.S. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J. Am. Heart Assoc. 2013, 2, e000250.
29. Mercaldi, C.J.; Siu, K.; Sander, S.D.; Walker, D.R.; Wu, Y.; Li, Q.; Wu, N. Long-term costs of ischemic stroke and major bleeding events among medicare patients with nonvalvular atrial fibrillation. Cardiol. Res. Pract. 2012, doi:10.1155/2012/645469.